참고문헌
-
Becouarn Y, Cany L, Pulido M, et al (2014). FOLFIRI
$^{(R)}$ and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes, 7, 260. https://doi.org/10.1186/1756-0500-7-260 - Buchler T, Pavlik T, Melichar B, et al (2014). Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer, 14, 323. https://doi.org/10.1186/1471-2407-14-323
- Cassidy J, Clarke S, Diaz‑Rubio E, et al (2011). XELOX vs FOLFOX‑4 as first‑line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer, 105, 58‑64. https://doi.org/10.1038/bjc.2011.201
- Cetin B, Kaplan MA, Berk V, et al (2012). Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factortargeting agents. Asian Pac J Cancer Prev, 13, 1059-63. https://doi.org/10.7314/APJCP.2012.13.3.1059
- Colucci G, Gebbia V, Paoletti G, et al (2005). Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol, 23, 4866-75. https://doi.org/10.1200/JCO.2005.07.113
- Cunningham D, Lang I, Marcuello E, et al (2013). Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol, 14, 1077-1085. https://doi.org/10.1016/S1470-2045(13)70154-2
- Doi T, Boku N, Kato K, et al (2010). Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first‑line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol, 40, 913‑920. https://doi.org/10.1093/jjco/hyq069
- Ducreux M, Adenis A, Pignon JP, et al (2013). Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer, 49,1236-45 https://doi.org/10.1016/j.ejca.2012.12.011
- Diaz-Rubio E, Gomez-Espana A, Massuti B, et al (2012). Firstline XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist, 17, 15-25 https://doi.org/10.1634/theoncologist.2011-0249
- Falcone A, Cremolini C, Masi G, et al (2013). FOLFOXIRI/ bevacizumab(bev) versus FOLFIRI/bev as first-line treatment in unresectablemetastatic colorectal cancer (mCRC) patients (pts): results of thephase III TRIBE trial by GONO Group. J Clin Oncol 31(Suppl.)[abstract 3505]
- Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76. https://doi.org/10.1038/nm0603-669
- Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86. https://doi.org/10.1200/JCO.2007.11.3357
- Grothey A, Sugrue M, Purdie D, et al (2008). Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol, 26, 5326-34. https://doi.org/10.1200/JCO.2008.16.3212
- Hasegawa J, Nishimura J, Mizushima T, et al (2014). Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol, 73, 1079-87. https://doi.org/10.1007/s00280-014-2417-9
- Hecht JR, Mitchell E, Chidiac T, et al (2009). A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol, 27, 672-680. https://doi.org/10.1200/JCO.2008.19.8135
- Hochster HS, Hart LL, Ramanathan RK, et al (2008). Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol, 26, 3523-9. https://doi.org/10.1200/JCO.2007.15.4138
- Kabbinavar FF, Hambleton J, Mass RD, et al (2005). Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol, 23, 3706-12. https://doi.org/10.1200/JCO.2005.00.232
- Lopez R, Salgado M, Reboredo M, et al (2010). A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer, 103, 1536-41. https://doi.org/10.1038/sj.bjc.6605938
- Macedo LT, Lima AB, Sasse AD (2012). Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer, 12, 89. https://doi.org/10.1186/1471-2407-12-89
- Pectasides D, Papaxoinis G, Kalogeras KT, et al (2012). XELIRIbevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer, 12, 271. https://doi.org/10.1186/1471-2407-12-271
- Rosati G, Avallone A, Aprile G, et al (2013). XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol, 71, 257-64. https://doi.org/10.1007/s00280-012-2004-x
- Sobrero A, Ackland S, Clarke S, et al (2009). Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology, 77, 113-9.
- Stathopoulos GP, Batziou C, Trafalis D, et al (2010). Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology, 78, 376-381. https://doi.org/10.1159/000320520
- Saltz LB, Clarke S, Diaz-Rubio E, et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26, 2013-19. https://doi.org/10.1200/JCO.2007.14.9930
- Sun J, Hu Y, Wu BS, et al (2014). Bevacizumab concomitant with chemotherapy is effective in treating Chinese patients with advanced non-squamous non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 5945-50. https://doi.org/10.7314/APJCP.2014.15.14.5945
- Temraz S, Mukherji D, Shamseddine A (2014). Sequencing of treatment in metastatic colorectal cancer: where to fit the target. World J Gastroenterol, 20, 1993-2004. https://doi.org/10.3748/wjg.v20.i8.1993
- Tol J, Koopman M, Cats A, et al 2009. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med, 360, 563-72. https://doi.org/10.1056/NEJMoa0808268
- Uchima Y, Nishii T, Iseki Y, et al (2014). Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer. Mol Clin Oncol, 2, 134-8
- Uygun K, Bilici A, Kaya S, et al (2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Asian Pac J Cancer Prev, 14, 2283-8. https://doi.org/10.7314/APJCP.2013.14.4.2283
- Van Cutsem E, Rivera F, Berry S, et al (2009). Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7. https://doi.org/10.1093/annonc/mdp233
- Welch S, Spithoff K, Rumble RB, Maroun J (2010). Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol, 21, 1152-62. https://doi.org/10.1093/annonc/mdp533
- Zhang YM, Li YQ, Liu ZH, et al (2014). Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 3447-50. https://doi.org/10.7314/APJCP.2014.15.8.3447
- Zhu LM, Zhao YZ, Ju HX, et al (2014). Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. Asian Pac J Cancer Prev, 15, 6559-64. https://doi.org/10.7314/APJCP.2014.15.16.6559